A recent publication from the Rega Institute for Medical Research features a number of RSV antivirals in clinical development including PC786. The authors conclude that PC786 elicited potent activity in differentiated human bronchial epithelium. In addition, treatment with PC786 resulted in a profound antiviral effect when first added to the infected cultures 3 post-infection. Drugs that are able to inhibit viral replication when added late after infection are believed to be beneficial as therapeutic agents.

Link to Publication

PDF